Skip to main content

Drug Utilization Review Board to Review New Drug Classes at October 23, 2020 Meeting

Last updated on 7/17/2020

Information posted July 17, 2020

At the Texas Drug Utilization Review (DUR) Board meeting on October 23, 2020, the DUR Board will perform a clinical review of anticonvulsants, antihemophilic, antineoplastic (i.e., anti-cancer), antiretroviral (i.e., anti-HIV), and medications used to treat multiple sclerosis (MS). These are protected drug classes not currently reviewed on the Texas Medicaid Preferred Drug List (PDL). All medications within these newly reviewed drug classes will be preferred and will continue to be available without prior authorization. 

Medications within these drug classes do not currently undergo clinical review for efficacy, clinical significance, or safety. Including these new drug classes on the PDL will allow the board to perform a clinical review of all medications in the following categories:

  • Anticonvulsants
  • Antihemophilic
  • Antineoplastic (anti-cancer)
  • Antiretroviral (anti-HIV)
  • Medications used to treat MS

Upon DUR Board review, all medications within these newly-reviewed drug classes will have a preferred status on the PDL and will continue to be available without prior authorization.

The July 24, 2020 board meeting will include a public announcement regarding the new drug classes to be reviewed at the October 23, 2020 meeting.

Contact vdp-advisory@hhsc.state.tx.us with comments or questions.